Literature DB >> 21548011

Congenital pancytopenia and absence of B lymphocytes in a neonate with a mutation in the Ikaros gene.

Frederick D Goldman1, Zafer Gurel, Duha Al-Zubeidi, Ari J Fried, Michael Icardi, Chunhua Song, Sinisa Dovat.   

Abstract

BACKGROUND: Congenital pancytopenia is a rare and often lethal condition. Current knowledge of lymphoid and hematopoietic development in mice, as well as understanding regulators of human hematopoiesis, have led to the recent discovery of genetic causes of bone marrow failure disorders. However, in the absence of mutations of specific genes or a distinct clinical phenotype, many cases of aplastic anemia are labeled as idiopathic, while congenital immune deficiencies are described as combined immune deficiency. PROCEDURE: We describe the case of a 33-week gestation age male with severe polyhydramnios, hydrops, and ascites who was noted to be pancytopenic at birth. Bone marrow examination revealed a hypocellular marrow with absent myelopoiesis. An immune workup demonstrated profound B lymphopenia, near absent NK cells, and normal T cell number. Due to the similarity of the patient's phenotype with the IKAROS knockout mouse, studies were performed on bone marrow and peripheral blood to assess a potential pathogenic role of Ikaros.
RESULTS: DNA studies revealed a point mutation in one allele of the IKAROS gene, resulting in an amino acid substitution in the DNA-binding zinc finger domain. Functional studies demonstrated that the observed mutation decreased Ikaros DNA-binding affinity, and immunofluorescence microscopy revealed aberrant Ikaros pericentromeric localization.
CONCLUSIONS: Our report describes a novel case of congenital pancytopenia associated with mutation of the IKAROS gene. Furthermore, these data suggest a critical role of IKAROS in human hematopoiesis and immune development.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21548011      PMCID: PMC3161153          DOI: 10.1002/pbc.23160

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  40 in total

1.  Ikaros DNA-binding proteins direct formation of chromatin remodeling complexes in lymphocytes.

Authors:  J Kim; S Sif; B Jones; A Jackson; J Koipally; E Heller; S Winandy; A Viel; A Sawyer; T Ikeda; R Kingston; K Georgopoulos
Journal:  Immunity       Date:  1999-03       Impact factor: 31.745

2.  Repression by Ikaros and Aiolos is mediated through histone deacetylase complexes.

Authors:  J Koipally; A Renold; J Kim; K Georgopoulos
Journal:  EMBO J       Date:  1999-06-01       Impact factor: 11.598

3.  Ikaros increases normal apoptosis in adult erythroid cells.

Authors:  Dianne Pulte; Rocio A Lopez; Shane T Baker; Maureen Ward; Ellen Ritchie; Christine A Richardson; David W O'Neill; Arthur Bank
Journal:  Am J Hematol       Date:  2006-01       Impact factor: 10.047

4.  Notch activation is an early and critical event during T-Cell leukemogenesis in Ikaros-deficient mice.

Authors:  Alexis Dumortier; Robin Jeannet; Peggy Kirstetter; Eva Kleinmann; MacLean Sellars; Nuno R dos Santos; Christelle Thibault; Jochen Barths; Jacques Ghysdael; Jennifer A Punt; Philippe Kastner; Susan Chan
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

5.  Human Ikaros function in activated T cells is regulated by coordinated expression of its largest isoforms.

Authors:  Tapani Ronni; Kimberly J Payne; Sam Ho; Michelle N Bradley; Glenn Dorsam; Sinisa Dovat
Journal:  J Biol Chem       Date:  2006-11-29       Impact factor: 5.157

6.  High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression.

Authors:  R P Kuiper; E F P M Schoenmakers; S V van Reijmersdal; J Y Hehir-Kwa; A Geurts van Kessel; F N van Leeuwen; P M Hoogerbrugge
Journal:  Leukemia       Date:  2007-04-19       Impact factor: 11.528

7.  The role of Ikaros in human erythroid differentiation.

Authors:  Marilyne Dijon; Florence Bardin; Anne Murati; Michèle Batoz; Christian Chabannon; Cécile Tonnelle
Journal:  Blood       Date:  2007-10-12       Impact factor: 22.113

8.  Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia.

Authors:  Charles G Mullighan; Salil Goorha; Ina Radtke; Christopher B Miller; Elaine Coustan-Smith; James D Dalton; Kevin Girtman; Susan Mathew; Jing Ma; Stanley B Pounds; Xiaoping Su; Ching-Hon Pui; Mary V Relling; William E Evans; Sheila A Shurtleff; James R Downing
Journal:  Nature       Date:  2007-04-12       Impact factor: 49.962

9.  Pre-T cell receptor (TCR) and TCR-controlled checkpoints in T cell differentiation are set by Ikaros.

Authors:  S Winandy; L Wu; J H Wang; K Georgopoulos
Journal:  J Exp Med       Date:  1999-10-18       Impact factor: 14.307

10.  Ikaros DNA-binding proteins as integral components of B cell developmental-stage-specific regulatory circuits.

Authors:  Elizabeth C Thompson; Bradley S Cobb; Pierangela Sabbattini; Sonja Meixlsperger; Vania Parelho; David Liberg; Benjamin Taylor; Niall Dillon; Katia Georgopoulos; Hassan Jumaa; Stephen T Smale; Amanda G Fisher; Matthias Merkenschlager
Journal:  Immunity       Date:  2007-03       Impact factor: 31.745

View more
  28 in total

Review 1.  Natural killer cell deficiency.

Authors:  Jordan S Orange
Journal:  J Allergy Clin Immunol       Date:  2013-09       Impact factor: 10.793

Review 2.  Emerging insights into human health and NK cell biology from the study of NK cell deficiencies.

Authors:  Emily M Mace; Jordan S Orange
Journal:  Immunol Rev       Date:  2019-01       Impact factor: 12.988

3.  Loss of B Cells in Patients with Heterozygous Mutations in IKAROS.

Authors:  H S Kuehn; B Boisson; M E Conley; S D Rosenzweig; C Cunningham-Rundles; J Reichenbach; A Stray-Pedersen; E W Gelfand; P Maffucci; K R Pierce; J K Abbott; K V Voelkerding; S T South; N H Augustine; J S Bush; W K Dolen; B B Wray; Y Itan; A Cobat; H S Sorte; S Ganesan; S Prader; T B Martins; M G Lawrence; J S Orange; K R Calvo; J E Niemela; J-L Casanova; T A Fleisher; H R Hill; A Kumánovics
Journal:  N Engl J Med       Date:  2016-03-17       Impact factor: 91.245

Review 4.  Casein Kinase II (CK2), Glycogen Synthase Kinase-3 (GSK-3) and Ikaros mediated regulation of leukemia.

Authors:  Chandrika Gowda; Mario Soliman; Malika Kapadia; Yali Ding; Kimberly Payne; Sinisa Dovat
Journal:  Adv Biol Regul       Date:  2017-06-13

5.  Cell cycle-specific function of Ikaros in human leukemia.

Authors:  Zhanjun Li; Chunhua Song; Hongsheng Ouyang; Liangxue Lai; Kimberly J Payne; Sinisa Dovat
Journal:  Pediatr Blood Cancer       Date:  2011-11-21       Impact factor: 3.167

Review 6.  Ikaros and tumor suppression in acute lymphoblastic leukemia.

Authors:  Kimberly J Payne; Sinisa Dovat
Journal:  Crit Rev Oncog       Date:  2011

7.  Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia.

Authors:  Chunhua Song; Chandrika Gowda; Xiaokang Pan; Yali Ding; Yongqing Tong; Bi-Hua Tan; Haijun Wang; Sunil Muthusami; Zheng Ge; Mansi Sachdev; Shantu G Amin; Dhimant Desai; Krishne Gowda; Raghavendra Gowda; Gavin P Robertson; Hilde Schjerven; Markus Muschen; Kimberly J Payne; Sinisa Dovat
Journal:  Blood       Date:  2015-07-28       Impact factor: 22.113

8.  Protein phosphatase 1 (PP1) and Casein Kinase II (CK2) regulate Ikaros-mediated repression of TdT in thymocytes and T-cell leukemia.

Authors:  Haijun Wang; Chunhua Song; Zafer Gurel; Na Song; Jisheng Ma; Hongsheng Ouyang; Liangxue Lai; Kimberly J Payne; Sinisa Dovat
Journal:  Pediatr Blood Cancer       Date:  2014-09-11       Impact factor: 3.167

Review 9.  Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment.

Authors:  Markus G Seidel
Journal:  Blood       Date:  2014-08-27       Impact factor: 22.113

Review 10.  IKAROS Family Zinc Finger 1-Associated Diseases in Primary Immunodeficiency Patients.

Authors:  Cristiane J Nunes-Santos; Hye Sun Kuehn; Sergio D Rosenzweig
Journal:  Immunol Allergy Clin North Am       Date:  2020-08       Impact factor: 3.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.